Published in J Exp Med on September 01, 1989
Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med (1990) 3.93
Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut (1993) 3.25
Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys (2005) 2.29
Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest (1993) 1.62
In vitro and in vivo activation of endothelial cells by colony-stimulating factors. J Clin Invest (1991) 1.31
Viral neuroinvasion and encephalitis induced by lipopolysaccharide and its mediators. J Exp Med (1992) 1.19
Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: in vivo and in vitro studies. Immunology (1996) 1.17
The effect of Mycobacterium tuberculosis on the susceptibility of human cells to the stimulatory and toxic effects of tumour necrosis factor. Immunology (1992) 1.16
Endothelial-monocyte activating polypeptide II, a novel antitumor cytokine that suppresses primary and metastatic tumor growth and induces apoptosis in growing endothelial cells. J Exp Med (1999) 1.13
Transient perturbation of endothelial integrity induced by natural antibodies and complement. J Exp Med (1995) 1.11
Alternative patterns of mitogenesis and cell scattering induced by acidic FGF as a function of cell density in a rat bladder carcinoma cell line. Cell Regul (1990) 1.02
Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br J Cancer (1996) 0.99
Role of cyclic AMP in promoting the thromboresistance of human endothelial cells by enhancing thrombomodulin and decreasing tissue factor activities. Br J Pharmacol (1993) 0.94
Endothelial tissue factor stimulation by proteinase 3 and elastase. Clin Exp Immunol (2001) 0.84
Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2. Br J Cancer (1992) 0.81
Synergistic antitumor effect of an angiogenesis inhibitor (TNP-470) and tumor necrosis factor in mice. Surg Today (2006) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Role of cell shape in growth control. Nature (1978) 12.46
Synthesis of antihemophilic factor antigen by cultured human endothelial cells. J Clin Invest (1973) 10.18
Immunization, isolation of immunoglobulins, estimation of antibody titre. Scand J Immunol Suppl (1973) 6.38
Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med (1986) 6.32
Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A (1986) 5.83
Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenyl glycoluril (Iodogen). Anal Biochem (1981) 5.49
Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med (1986) 5.17
Protein iodination with solid state lactoperoxidase. Biochemistry (1974) 4.52
Selection and characterization of bovine aortic endothelial cells. In Vitro (1978) 4.09
Cellular receptor for 125I-labeled tumor necrosis factor: specific binding, affinity labeling, and relationship to sensitivity. Proc Natl Acad Sci U S A (1985) 2.92
The inhibition of blood coagulation by activated Protein C through the selective inactivation of activated Factor V. Biochim Biophys Acta (1979) 2.83
Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins. J Exp Med (1989) 2.69
Cachectin/tumor necrosis factor exerts endocrine, paracrine, and autocrine control of inflammatory responses. J Cell Biol (1988) 2.66
Structure of tumour necrosis factor. Nature (1989) 2.62
The regulation of natural anticoagulant pathways. Science (1987) 2.58
Purification and characterization of bovine tissue factor. J Biol Chem (1981) 1.99
The active form of tumor necrosis factor is a trimer. J Biol Chem (1987) 1.86
Cellular requirements for tissue factor generation by bovine aortic endothelial cells in culture. Thromb Res (1985) 1.83
Initiation of coagulation by tissue factor. CRC Crit Rev Biochem (1988) 1.73
Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. J Exp Med (1988) 1.71
Participation of endothelial cells in the protein C-protein S anticoagulant pathway: the synthesis and release of protein S. J Cell Biol (1986) 1.68
Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood (1989) 1.64
A high molecular weight component of the human tumor necrosis factor receptor is associated with cytotoxicity. Proc Natl Acad Sci U S A (1987) 1.54
Matrix-driven cell size change modulates aortic endothelial cell proliferation and sheet migration. Am J Pathol (1988) 1.49
Quantification and characterization of high-affinity membrane receptors for tumor necrosis factor on human leukemic cell lines. Int J Cancer (1986) 1.45
Tumour necrosis factor (cachectin) induces phospholipase A2 activity and synthesis of a phospholipase A2-activating protein in endothelial cells. Biochem J (1988) 1.42
The role of membrane-membrane interactions in the regulation of endothelial cell growth. J Cell Biol (1985) 1.41
Effects of cytoskeletal disrupting agents on replication of bovine endothelium. J Cell Physiol (1981) 1.19
Down regulation of the receptors for tumor necrosis factor by interleukin 1 and 4 beta-phorbol-12-myristate-13-acetate. J Immunol (1987) 1.12
The effect of bovine thrombomodulin on the specificity of bovine thrombin. J Biol Chem (1986) 1.12
In vitro reendothelialization. Microfilament bundle reorganization in migrating porcine endothelial cells. Arteriosclerosis (1984) 1.08
Binding and crosslinking of 125I-labeled recombinant human tumor necrosis factor to cell surface receptors. J Biochem (1986) 0.98
The human interleukin-2 receptor: a molecular and biochemical analysis of structure and function. Clin Res (1987) 0.97
Rapid modulation of tumor necrosis factor membrane receptors by activators of protein kinase C. Biochem Biophys Res Commun (1986) 0.94
Resistance to the cytolytic action of lymphotoxin and tumor necrosis factor coincides with the presence of gap junctions uniting target cells. J Immunol (1987) 0.94
Endothelial cell procoagulant properties and the host response. Semin Thromb Hemost (1987) 0.94
Radiosensitivity of human endothelial cells in culture. J Lab Clin Med (1974) 0.93
Tumor necrosis factor and immune interferon act in concert to slow the lateral diffusion of proteins and lipids in human endothelial cell membranes. J Cell Biol (1988) 0.91
Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science (2001) 15.54
Accessing genetic information with high-density DNA arrays. Science (1996) 13.89
RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell (1999) 8.55
The Berkeley Drosophila Genome Project gene disruption project: Single P-element insertions mutating 25% of vital Drosophila genes. Genetics (1999) 7.56
RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature (1996) 7.04
Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem (1992) 5.60
Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med (1998) 5.54
The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem (1995) 5.36
Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med (1986) 5.17
Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med (1990) 3.93
Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem (1994) 3.73
N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem (1999) 3.72
Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem (1992) 3.64
Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins. J Exp Med (1989) 2.69
Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res (1999) 2.59
Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med (1989) 2.52
Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med (2000) 2.44
An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease. Nature (1997) 2.42
Context, conflict, and resolution: a new conceptual framework for evaluating professionalism. Acad Med (2000) 2.39
Hypoxia-mediated induction of endothelial cell interleukin-1 alpha. An autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface. J Clin Invest (1992) 2.34
Sequence organization of the spacer in the ribosomal genes of Xenopus clivii and Xenopus borealis. Nucleic Acids Res (1981) 2.27
Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc Natl Acad Sci U S A (1990) 2.18
The nucleotide sequence of the initiation region of the ribosomal transcription unit from mouse. Nucleic Acids Res (1981) 2.16
Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb (1994) 2.05
Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest (1996) 2.03
Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan. J Biol Chem (1986) 2.02
Purification and characterization of bovine tissue factor. J Biol Chem (1981) 1.99
Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest (1993) 1.99
Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol (2000) 1.92
Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci U S A (1994) 1.91
An endothelial cell-dependent pathway of coagulation. Proc Natl Acad Sci U S A (1985) 1.90
A study of lower-limb mechanics during stair-climbing. J Bone Joint Surg Am (1980) 1.89
Tissue factor revisited. Prog Hemost Thromb (1982) 1.86
Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci U S A (1994) 1.85
Hypoxia modulates the barrier and coagulant function of cultured bovine endothelium. Increased monolayer permeability and induction of procoagulant properties. J Clin Invest (1990) 1.84
Cellular requirements for tissue factor generation by bovine aortic endothelial cells in culture. Thromb Res (1985) 1.83
Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci U S A (1997) 1.82
Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci U S A (1994) 1.71
Isolation of cDNA clones coding for human tissue factor: primary structure of the protein and cDNA. Proc Natl Acad Sci U S A (1987) 1.71
Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. J Exp Med (1988) 1.71
GENESIS, a knowledge-based genetic engineering simulation system for representation of genetic data and experiment planning. Nucleic Acids Res (1982) 1.70
Participation of endothelial cells in the protein C-protein S anticoagulant pathway: the synthesis and release of protein S. J Cell Biol (1986) 1.68
Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine. Biochemistry (1986) 1.68
Risk factors associated with human cystic echinococcosis in Florida, Uruguay: results of a mass screening study using ultrasound and serology. Am J Trop Med Hyg (1998) 1.68
Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am J Pathol (1994) 1.62
The usefulness of a tracking catheter in complex coronary angioplasty. Cathet Cardiovasc Diagn (1992) 1.60
Induction of interleukin 6 (IL-6) by hypoxia in vascular cells. Central role of the binding site for nuclear factor-IL-6. J Biol Chem (1995) 1.58
Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia. Proc Natl Acad Sci U S A (1998) 1.57
Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J Clin Invest (1998) 1.51
Markedly elevated creatinine phosphokinase, cotton wool spots, and pericarditis in a patient with leptospirosis. Gastroenterology (1981) 1.47
Management of hypertension in twelve Oxfordshire general practices. J R Coll Gen Pract (1986) 1.43
Macrovascular and microvascular endothelium during long-term hypoxia: alterations in cell growth, monolayer permeability, and cell surface coagulant properties. J Cell Physiol (1991) 1.42
Naive neutrophils and xenotransplantation. Lancet (1996) 1.41
Endothelial monocyte-activating polypeptide II. A novel tumor-derived polypeptide that activates host-response mechanisms. J Biol Chem (1992) 1.40
beta-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1. Am J Physiol Cell Physiol (2000) 1.40
Breast screening: adverse psychological consequences one month after placing women on early recall because of a diagnostic uncertainty. A multicentre study. J Med Screen (1997) 1.40
Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Aypass Angioplasty Revascularization Investigation (BARI). Circulation (1999) 1.39
Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals. J Exp Med (1995) 1.37
Transcriptional and post-transcriptional control of plastid mRNA levels in higher plants. Trends Genet (1988) 1.34
RAGE: a novel cellular receptor for advanced glycation end products. Diabetes (1996) 1.34
Induction of spectrin in erythroleukemic cells transformed by Friend virus. Proc Natl Acad Sci U S A (1977) 1.33
Inhibition by colchicine and by vinblastine of acetylcholine-induced catecholamine release from the adrenal gland: an anticholinergic action, not an effect upon microtubules. Mol Pharmacol (1972) 1.31
An inhibitory monoclonal antibody against human tissue factor. Blood (1987) 1.30
Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res (1983) 1.29
An outbreak of hepatitis associated with intravenous injection of factor-VIII concentrate. Lancet (1975) 1.27
Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci U S A (1994) 1.25
Hypoxia induces glucose transporter expression in endothelial cells. Am J Physiol (1992) 1.22
Role of smooth muscle cell death in advanced coronary primary lesions: implications for plaque instability. Cardiovasc Res (1999) 1.20
Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J Neurosci (2001) 1.20
Characterization of vascular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytes. Blood (1993) 1.20
Interleukin-6 gene expression in human endothelial cells: RNA start sites, multiple IL-6 proteins and inhibition of proliferation. Biochem Biophys Res Commun (1989) 1.19
Tumor necrosis factor enhances expression of tissue factor mRNA in endothelial cells. Thromb Res (1989) 1.19
Activation of coagulation releases endothelial cell mitogens. J Cell Biol (1986) 1.16
Initiation codon mutations in the Chlamydomonas chloroplast petD gene result in temperature-sensitive photosynthetic growth. EMBO J (1993) 1.15
Induction of myocardial nitric oxide synthase by cardiac allograft rejection. J Clin Invest (1994) 1.13
Endothelial-monocyte activating polypeptide II, a novel antitumor cytokine that suppresses primary and metastatic tumor growth and induces apoptosis in growing endothelial cells. J Exp Med (1999) 1.13
Hypoxia-induced increased permeability of endothelial monolayers occurs through lowering of cellular cAMP levels. Am J Physiol (1992) 1.12
Synthesis and release of interleukin 1 by reoxygenated human mononuclear phagocytes. J Clin Invest (1992) 1.10
Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation. Lab Invest (2000) 1.10
Cardiac preservation is enhanced in a heterotopic rat transplant model by supplementing the nitric oxide pathway. J Clin Invest (1994) 1.10